<<

17

Heparin: May prolong whole blood– aspirin (acetylsalicylic acid) activated clotting time. A.S.A., Ascriptin, Bayer Timed-Release, Bufferin, Ecotrin argatroban Argatroban Salicylate; nonopioid analgesic, anti- pyretic, anti-inflammatory, aggre- Direct inhibitor; gation inhibitor PRC: B PRC: D

Available forms Available forms Injection: 100 mg/ml Chewing gum: 227.5 mg; Suppositories: 120, 200, 300, 600 mg; Tablets: 325, Indications & dosages 500 mg; Tablets (chewable): 81 mg; ➤ Prophylaxis or treatment of Tablets (controlled-release): 800 mg; in patients with -induced thrombo- Tablets (delayed-release, enteric-coated): cytopenia (HIT)—Adult: 2 mcg/kg/min as 81, 165, 325, 500, 650, 975 mg; Tablets continuous IV infusion; adjust dose until (timed-release): 650 mg steady-state aPTT is 1.5-3 times initial baseline value, not to exceed 100 sec; Indications & dosages max dose 10 mcg/kg/min.‡ ➤ RA, other inflammatory conditions— ➤ Anticoagulation in patients with or at Adult: 2.4-3.6 g PO daily in divided doses. risk for HIT during percutaneous coro- Maintenance 3.2-6 g PO daily in divided nary interventions—Adults: 350 mcg/kg doses. IV bolus over 3-5 min. Start continuous IV ➤ Pain, fever—Adult, child > 11 yr: 325- infusion at 25 mcg/kg/min. Activated clot- 650 mg PO or PR q 4 hr prn. Child 2- ting time should be checked 5-10 min af- 11 yr: 10-15 mg/kg PO or PR q 4 hr; max ter bolus dose is completed and dosage 60-80 mg/kg/d. adjusted prn. ➤ MI prophylaxis—Adult: 300-325 mg PO daily. Interactions Oral : May prolong PT and Interactions INR and increase risk of bleeding. Aminoglycosides, bumetanide, capreo- Thrombolytics: May increase risk of intra- mycin, cisplatin, erythromycin, ethacrynic cranial bleeding. acid, furosemide, vancomycin: May po- tentiate ototoxic effects. Ammonium chloride, other urine acidi- fiers: May increase blood aspirin level. Antacids in high doses, other urine alka- lizers: May decrease blood aspirin level.

§ Adjust in immunocompromised patients ¶ Adjust in debilitated patients